Eli Lilly to release late-stage data on next-generation weight loss drug retatrutide in 2025, earlier than expected
Eli Lilly expects to read out results from a study in people with obesity and osteoarthritis of the knee in 2025.
Nature9d
The weight-loss drugs being tested in 2025: will they beat Ozempic?
In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...
NBC 10 Philadelphia8d
Eli Lilly to release late-stage data on next-generation weight loss drug retatrutide in 2025, earlier than expected
Novo Nordisk's weight loss drug Wegovy mimics only GLP-1. Retatrutide appears to cause even greater weight loss than tirzepatide, which has skyrocketed in demand in the U.S. Retatrutide helped ...